21st North Inc. (formerly known as Urologix, Inc.) Announces Expected Timeline for Administrative Dissolution of the Company
April 25, 2016 15:05 ET
|
21st North Inc.
MINNEAPOLIS, April 25, 2016 (GLOBE NEWSWIRE) -- 21st North Inc. announced today that its reconvened Special Meeting of Shareholders commenced earlier today again failed to achieve a quorum. ...
21st North Inc. Announces Special Meeting of Shareholders to Approve the Plan of Dissolution to be Reconvened April 25, 2016
March 29, 2016 17:12 ET
|
21st North Inc.
MINNEAPOLIS, March 29, 2016 (GLOBE NEWSWIRE) -- 21st North Inc. (formerly known as Urologix, Inc.) announced today that its Special Meeting of Shareholders commenced earlier today was adjourned...
Urologix Announces Sale of Operating Assets to Private Company Buyer
February 02, 2016 16:05 ET
|
21st North Inc.
MINNEAPOLIS, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTC Pink:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today...
Urologix Announces SEC Deregistration
July 09, 2015 16:00 ET
|
21st North Inc.
MINNEAPOLIS, July 09, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced...
Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans
May 21, 2015 16:00 ET
|
21st North Inc.
MINNEAPOLIS, May 21, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data...
Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans
May 12, 2015 16:01 ET
|
21st North Inc.
MINNEAPOLIS, May 12, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an...
Urologix Reports Third Quarter Fiscal Year 2015 Results
May 12, 2015 16:00 ET
|
21st North Inc.
Recent Quarter Results Revenue $2.8 MillionEnding cash balances, including restricted cash of $532,000$2.8 million owed under the Prostiva license and Medtronic promissory note remains past...
Urologix Announces Hiring of Chief Financial Officer
March 23, 2015 09:00 ET
|
21st North Inc.
MINNEAPOLIS, March 23, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the...
Urologix Reports Second Quarter Fiscal Year 2015 Results
February 05, 2015 16:00 ET
|
21st North Inc.
Recent Quarter Highlights
Revenue $3.1 Million, 2% increase from first quarter fiscal year 2015.
Net loss reduced by 67% to $357,000 from a net loss of $1.1 million in the second quarter of...
Urologix Reports Preliminary Fiscal Year 2015 Second Quarter Revenue and Cash Results
January 12, 2015 08:00 ET
|
21st North Inc.
Second quarter preliminary revenue of $3.1M, up 2% sequentially
MINNEAPOLIS, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for...